2 Information about lesinurad

2 Information about lesinurad

Information about lesinurad

Marketing authorisation

Lesinurad (Zurampic, Grünenthal) taken with a xanthine oxidase inhibitor has a marketing authorisation for treating hyperuricaemia in adults with gout, with or without tophi, whose serum uric acid is above the target level with an adequate dose of a xanthine oxidase inhibitor alone.

Licensed xanthine oxidase inhibitors include allopurinol and febuxostat.

Dosage in the marketing authorisation

The recommended dose of lesinurad is 200 mg, administered orally daily in the morning. This is also the maximum dose (see section 4.4 of the summary of product characteristics). Lesinurad tablets must be given at the same time as the morning dose of a xanthine oxidase inhibitor, that is, allopurinol or febuxostat. The recommended minimum dose of allopurinol is 300 mg, or 200 mg for patients with moderate renal impairment (creatinine clearance 30–59 ml/min). If treatment with the xanthine oxidase inhibitor is interrupted, lesinurad dosing must also be interrupted.


The company stated that the list price is £27.90 per 30‑pack of 200-mg tablets. Costs may vary in different settings because of negotiated procurement discounts.

  • National Institute for Health and Care Excellence (NICE)